Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

BACKGROUND: Gefitinib is an orally potent and selective ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and is commonly used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations. Multiple adverse effects associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Zhang, Jingui, Zhou, Simin, Yu, Limei, Han, Fangxuan, Ling, Ren, Ling, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377447/
https://www.ncbi.nlm.nih.gov/pubmed/32702075
http://dx.doi.org/10.1371/journal.pone.0236523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377447/
https://www.ncbi.nlm.nih.gov/pubmed/32702075
http://dx.doi.org/10.1371/journal.pone.0236523

Ejemplares similares